UBS Group’s BioTelemetry, Inc. BEAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-55,201
Closed -$3.98M 9965
2020
Q4
$3.98M Buy
55,201
+14,969
+37% +$784K ﹤0.01% 2698
2020
Q3
$1.83M Sell
40,232
-40,196
-50% -$1.68M ﹤0.01% 3129
2020
Q2
$3.63M Sell
80,428
-1,106
-1% -$49.6K ﹤0.01% 2319
2020
Q1
$3.14M Sell
81,534
-48,742
-37% -$2.24M ﹤0.01% 2340
2019
Q4
$6.03M Buy
130,276
+33,396
+34% +$1.45M ﹤0.01% 2436
2019
Q3
$3.95M Buy
96,880
+18,007
+23% +$777K ﹤0.01% 2603
2019
Q2
$3.8M Buy
78,873
+17,506
+29% +$920K ﹤0.01% 2558
2019
Q1
$3.84M Sell
61,367
-11,302
-16% -$776K ﹤0.01% 2416
2018
Q4
$4.34M Buy
72,669
+6,429
+10% +$386K ﹤0.01% 2277
2018
Q3
$4.27M Sell
66,240
-13,197
-17% -$736K ﹤0.01% 2495
2018
Q2
$3.57M Sell
79,437
-6,915
-8% -$276K ﹤0.01% 2632
2018
Q1
$2.68M Sell
86,352
-2,390
-3% -$78.6K ﹤0.01% 2882
2017
Q4
$2.65M Sell
88,742
-19,203
-18% -$556K ﹤0.01% 2945
2017
Q3
$3.56M Buy
107,945
+23,677
+28% +$820K ﹤0.01% 2550
2017
Q2
$2.82M Sell
84,268
-33,432
-28% -$997K ﹤0.01% 2684
2017
Q1
$3.41M Buy
117,700
+33,184
+39% +$822K ﹤0.01% 2439
2016
Q4
$1.89M Buy
84,516
+39,507
+88% +$772K ﹤0.01% 2959
2016
Q3
$836K Buy
45,009
+597
+1% +$11.3K ﹤0.01% 3550
2016
Q2
$724K Sell
44,412
-635
-1% -$9.34K ﹤0.01% 3626
2016
Q1
$526K Sell
45,047
-1,203
-3% -$13.4K ﹤0.01% 3736
2015
Q4
$540K Sell
46,250
-1,390
-3% -$17.6K ﹤0.01% 3883
2015
Q3
$583K Sell
47,640
-5,936
-11% -$75.7K ﹤0.01% 3769
2015
Q2
$505K Sell
53,576
-4,000
-7% -$37K ﹤0.01% 4113
2015
Q1
$510K Sell
57,576
-8,955
-13% -$90.5K ﹤0.01% 4126
2014
Q4
$668K Buy
+66,531
New +$571K ﹤0.01% 3931

Other funds holding BEAT

UBS Group's BEAT Position: Q1 2021 in Review

UBS Group sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 55,201 shares — an estimated $3.98M sold.

UBS Group first reported a position in BEAT in Q4 2014 and held it in 25 quarters. The position peaked at $6.03M in Q4 2019. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

  • UBS Group reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
  • UBS Group sold 55,201 BioTelemetry, Inc. shares in Q1 2021, an estimated $3.98M.
  • UBS Group first reported a position in BioTelemetry, Inc. in Q4 2014 and held it in 25 quarters.
  • UBS Group's BioTelemetry, Inc. position peaked at $6.03M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on UBS Group's 13F filing for Q1 2021, filed 12 May 2021.